DAIICHI SANKYO, INC.
- Country
- 🇯🇵Japan
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 36
- Registration Number
- NCT03614455
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Dallas, Texas, United States
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 10
- Registration Number
- NCT03552029
- Locations
- 🇺🇸
Ronald Reagan Medical Center, UCLA, Los Angeles, California, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸University of Kansas Cancer Center, Fairway, Kansas, United States
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 524
- Registration Number
- NCT03529110
- Locations
- 🇺🇸
UCLA Hematology Oncology, Los Angeles, California, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 608
- Registration Number
- NCT03523585
- Locations
- 🇺🇸
Ironwood Cancer Research Centers, Chandler, Arizona, United States
🇺🇸UCLA Hematology Oncology - Main Site, Los Angeles, California, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
- Conditions
- Breast CancerUrothelial Carcinoma
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 86
- Registration Number
- NCT03523572
- Locations
- 🇺🇸
UCLA - Medical Center, Santa Monica, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸University of Miami Hospital & Clinics/Sylvester Comprehensive Cancer Center, Miami, Florida, United States
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 181
- Registration Number
- NCT03505710
- Locations
- 🇺🇸
University of California San Diego (UCSD), La Jolla, California, United States
🇺🇸University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 168
- Registration Number
- NCT03395639
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cardon Childrens Medical Center, Mesa, Arizona, United States
🇺🇸Cedars Sinai Medical Center (ECG), Los Angeles, California, United States
DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT03316729
DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis
- Conditions
- Hyperphosphatemia
- Interventions
- First Posted Date
- 2017-10-10
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 40
- Registration Number
- NCT03305471
- Locations
- 🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Prism Clinical Research, Saint Paul, Minnesota, United States
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
- Conditions
- Drug Interaction Potential
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 32
- Registration Number
- NCT03291288
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸Stanford University, Palo Alto, California, United States